Potential role of various dosimetric quality indicators in prostate brachytherapy

This publication has 31 references indexed in Scilit:

• Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma
  Cancer, 1997
• Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer
  Urology, 1997
• Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate
  International Journal of Radiation Oncology*Biology*Physics, 1997
• Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.
  Journal of Clinical Oncology, 1996
• 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma
  International Journal of Radiation Oncology*Biology*Physics, 1996
• Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma.
  Journal of Clinical Oncology, 1996
• 79 Long-term outcomes of external beam irradiation and I-125/Pd-103 brachytherapy boost for prostate cancer
  International Journal of Radiation Oncology*Biology*Physics, 1996
• Prostate Specific Antigen Based Disease Control Following Ultrasound Guided sup 125 Iodine Implantation for Stage T1/T2 Prostatic Carcinoma
  Journal of Urology, 1995
• Short-term freedom from disease progression after I-125 prostate implantation
  International Journal of Radiation Oncology*Biology*Physics, 1994
• Brachytherapy and organ preservation in the management of carcinoma of the prostate
  Seminars in Radiation Oncology, 1993